Business Context and Reporting Period
This Form 8-K is a current report filed by Aprea Therapeutics, Inc. on January 23, 2026. The filing addresses a regulatory notice regarding the continued listing of the Company's common stock on The Nasdaq Capital Market under the symbol "APRE".
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the Company's stock price performance relative to Nasdaq listing standards.
Material Changes and Events
- Deficiency Notice: The Company received a deficiency letter from Nasdaq stating that for the last 30 consecutive business days, the closing bid price of its common stock has been below the $1.00 per share minimum required by Nasdaq Listing Rule 5550(a)(2).
- Current Status: The deficiency letter has no immediate effect on the listing; the stock continues to trade on Nasdaq.
- Compliance Period: The Company has been granted an initial compliance period of 180 calendar days, ending on July 22, 2026.
- Compliance Criteria: To regain compliance, the Company must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days within the 180-day window.
Outlook, Risks, and Management Commentary
- Delisting Risk: If the Company fails to regain compliance by July 22, 2026, its common stock will become subject to delisting.
- Secondary Compliance Period: If the initial period expires without compliance, the Company may be eligible for a second 180-day period if it meets other listing standards (e.g., market value of publicly held shares) and notifies Nasdaq of its intent to cure the deficiency.
- Appeal Rights: In the event of a delisting determination, the Company retains the right to appeal to a Nasdaq hearings panel.
- Management Action: The Company intends to monitor the stock price and may consider options to regain compliance, including a reverse stock split. Management explicitly states there can be no assurance that compliance will be achieved.
Investor Verification Checklist
- Verify the current closing bid price of APRE to assess the gap from the $1.00 threshold.
- Monitor official announcements for any declaration of a reverse stock split.
- Track the 10 consecutive business days of $1.00+ closing prices required to cure the deficiency.
- Review the Company's market value of publicly held shares to determine eligibility for a second compliance period if the first is missed.
- Watch for any subsequent 8-K filings regarding the outcome of the compliance period or delisting appeals.